Pre-Market Money Movers

by @tabber

NOV 16, 2026

SMMT — -18% premarket as FDA rejects lung cancer drug ivonescimab

SMMT−18% downFDA

Summit said Sunday the FDA issued a Complete Response Letter for ivonescimab in EGFR-mutated lung cancer, saying the application cannot be approved in its current form because the HARMONi trial showed a progression-free survival benefit but no statistically significant overall-survival gain. The decision halts the near-term U.S. launch of Summit's flagship drug; the company says it will review the letter and engage with the FDA on next steps.

Read full analysis on healthandfamily.in ↗
Useful?